Tag: AstraZeneca
Executive pay debate intensifies with proxy advisors in the firing line
Big pharma chair Michel Demaré points to proxy advisors as cause of block on higher pay while more FTSE 100 companies plan boost to packages.
Should UK CEO pay be increased?
There are unanswered questions about the nature of competition between UK and US businesses that need to be considered first.
Diageo announces NED appointment
GSK’s Julie Brown will join the board of directors as a non-executive director and auditco chair on 5 August.
Deliveroo appoints non-executive director
Technology specialist Shobie Ramakrishnan will join the global online food delivery company as a NED in January.
Smith+Nephew appoints NEDs
Jeremy Maiden joins the board as a non-executive director today, with Simon Lowth taking up his role on 1 January.
AstraZeneca announces chair succession
Michel Demaré has been appointed chair-designate and will take over from Leif Johansson, who retires in April next year.
AstraZeneca appoints Aradhana Sarin as chief financial officer
Sarin is currently CFO of US rare diseases specialist Alexion, which is in the process of being acquired by AstraZeneca in a $39bn deal.
‘Repeat offenders’ warned to heed shareholder revolts
The Investment Association has written warning letters to 32 “repeat offender” companies who saw revolts over the same issues for two years running.
Broaden evaluation of foreign investors’ intentions, urges EEF
Plans to broaden takeover rules should go much further, covering the impact of foreign investor-led deals on UK supply chains and skills base, says lobby group EEF.
Shareholder displeasure against S&P500 directors reaches high level
Withholding of votes reaches peak level, sending a signal that shareholders are unhappy with S&P500 directors.